肿瘤坏死对鼻咽癌治疗敏感性和长期生存的影响
该回顾性研究纳入757例接受调强放疗的非转移性鼻咽癌患者,评估肿瘤坏死对治疗敏感性和长期生存的影响。结果显示肿瘤坏死患者完全缓解率更低,7年OS、FFS、DMFS和LRRFS均更差,多因素分析证实肿瘤坏死是独立预后因素。淋巴结坏死可改善现有N分期的预测价值。
要点
- 肿瘤坏死患者完全缓解率40.8%,无坏死患者54.7%(P<0.001)。
- 肿瘤坏死患者7年OS、FFS、DMFS和LRRFS均显著低于无坏死患者(均P<0.001)。
- 淋巴结坏死可改善现有N分期的预测价值(P=0.006)。
核心结论
- 肿瘤坏死是鼻咽癌治疗敏感性和不良预后的预测因素。
- 淋巴结坏死显著改善现有N分期的预后价值。
研究设计与样本
- 回顾性分析757例经组织学确诊的非转移性鼻咽癌患者,均接受调强放疗,93.7%的T3-T4/N1-N3期患者接受顺铂为基础的化疗。
主要发现
- 原发灶、咽后淋巴结、颈部淋巴结和总肿瘤的坏死发生率分别为2%、17.7%、21.5%和31.4%。
- 总肿瘤坏死患者完全缓解率40.8%,无坏死患者54.7%(χ2=12.728,P<0.001)。
- 总肿瘤坏死与无坏死患者的7年OS分别为68.5% vs. 88.4%,FFS为70.5% vs. 88.1%,DMFS为77.6% vs. 90.6%,LRRFS为85.9% vs. 91.3%(均P<0.001)。
- 多因素分析显示总肿瘤坏死是OS、FFS、DMFS和LRRFS的独立预测因素。
- 淋巴结坏死对长期生存的影响与总肿瘤坏死相似,ROC曲线证实纳入淋巴结坏死改善现有N分期的预测价值(P=0.006)。
关键数值与推荐
- 总肿瘤坏死患者完全缓解率40.8%,无坏死患者54.7%(χ2=12.728,P<0.001)。
- 总肿瘤坏死与无坏死患者7年OS分别为68.5% vs. 88.4%(P<0.001)。
- 总肿瘤坏死与无坏死患者7年FFS分别为70.5% vs. 88.1%(P<0.001)。
- 总肿瘤坏死与无坏死患者7年DMFS分别为77.6% vs. 90.6%(P<0.001)。
- 总肿瘤坏死与无坏死患者7年LRRFS分别为85.9% vs. 91.3%(P<0.001)。
临床怎么用
- 可将肿瘤坏死作为鼻咽癌预后评估和治疗敏感性预测的参考指标。
- 淋巴结坏死信息有助于改善现有N分期的预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the impact of tumor necrosis on treatment sensitivity and long-term survival in patients with nasopharyngeal carcinoma (NPC) treated using intensity-modulated radiation therapy (IMRT). PARTICIPANTS AND METHODS: In total, 757 patients with non-metastatic, histologically confirmed NPC were retrospectively examined. All patients were treated using IMRT; 93.7% patients with stage T3-T4/N1-N3 disease also received cisplatin-based chemotherapy. RESULTS: The incidence rates of tumor necrosis in primary tumor, retropharyngeal lymph nodes, neck lymph nodes, and total tumor were 2%, 17.7%, 21.5%, and 31.4%. Overall, 40.8% patients with necrosis of the total tumor achieved complete response (CR) and 54.7% patients without tumor necrosis achieved CR at the end of treatment (χ2 = 12.728, P < 0.001). The estimated 7-year overall survival (OS), failure-free survival (FFS), distant metastasis-free survival (DMFS), and loco-regional relapse-free survival (LRRFS) for patients with tumor necrosis and without tumor necrosis of the total tumor were 68.5% vs. 88.4%, 70.5% vs. 88.1%, 77.6% vs. 90.6%, and 85.9% vs. 91.3%, respectively (all P < 0.001). Multivariate analyses indicated that necrosis of the total tumor was an independent predictor of OS, FFS, DMFS, and LRRFS. The impact of lymph node necrosis on long-term survival was similar to that of necrosis of the total tumor. ROC curves verified that inclusion of lymph node necrosis improved the predictive value of the current N classification criteria (P = 0.006). CONCLUSIONS: Tumor necrosis served as a predictor of treatment sensitivity and poor prognosis for patients with NPC. Lymph node necrosis significantly improved the prognostic value of the current N classification criteria for NPC.
引用
- Liang SB, Chen LS, Yang XL, et al. Influence of tumor necrosis on treatment sensitivity and long-term survival in nasopharyngeal carcinoma. Radiother Oncol. 2020. PMID: 33217495. doi:10.1016/j.radonc.2020.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。